

Exploring Clinical Investigator Perspectives on the Optimal Management of Chronic Lymphocytic Leukemia (Medical and Hematologic Oncologists)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which conclusion best reflects the progression-free survival (PFS) findings from the Phase III Alliance A041202 study evaluating ibrutinib alone versus ibrutinib/rituximab (IR) or bendamustine/rituximab (BR) for older patients with previously untreated CLL?**
 - a. Ibrutinib alone was superior to BR
 - b. IR was superior to BR
 - c. BR was superior to ibrutinib alone
 - d. Ibrutinib alone and IR were both superior to BR
- 2. Which of the following statements is true regarding the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib when compared to ibrutinib?**
 - a. Acalabrutinib is less selective for BTK with more off-target effects
 - b. Acalabrutinib is more selective for BTK with fewer off-target effects
 - c. Acalabrutinib is similar with about the same number of off-target effects
- 3. The Phase III ELEVATE-TN trial comparing acalabrutinib or acalabrutinib/obinutuzumab to chlorambucil/obinutuzumab for patients with previously untreated CLL demonstrated which of the following efficacy outcomes?**
 - a. PFS was significantly improved with acalabrutinib monotherapy only versus chlorambucil/obinutuzumab
 - b. PFS was significantly improved with acalabrutinib/obinutuzumab only versus chlorambucil/obinutuzumab
 - c. PFS was significantly improved in both acalabrutinib-containing arms versus chlorambucil/obinutuzumab
- 4. Results of the Phase III CLL14 study demonstrated improved outcomes with which regimen compared to chlorambucil/obinutuzumab for patients with previously untreated CLL and coexisting medical conditions?**
 - a. Venetoclax/rituximab
 - b. Venetoclax/obinutuzumab
 - c. Bendamustine/obinutuzumab
- 5. The ongoing Phase III EA9161 and A041702 studies are evaluating ibrutinib/obinutuzumab with or without which agent for patients with previously untreated CLL?**
 - a. Acalabrutinib
 - b. Nivolumab
 - c. Venetoclax